Impact of SARS-CoV-2 Infection on Patients with Cancer: Retrospective and Transversal Studies in Spanish Population
Abstract
:Simple Summary
Abstract
1. Introduction
2. Material and Methods
2.1. Study Design and Participants
2.2. Study Variables
2.3. Statistical Analysis
2.4. Ethical Considerations
3. Results
3.1. Retrospective Study of Patients with Cancer Hospitalized with PCR Confirmed Diagnose of COVID-19 (Cohort 1)
3.2. Transversal Study of Patients Treated with Anticancer Therapies. Cohort 2
4. Discussion
5. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Adhanom Ghebreyesus, T. WHO—Director-General’s Opening Remarks at the Media Briefing on COVID-19; World Health Organization: Geneva, Switzerland, 11 March 2020; Available online: www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-11-march-2020 (accessed on 11 March 2020).
- Munster, V.J.; Koopmans, M.; Van Doremalen, N.; Van Riel, D.; De Wit, E. A Novel Coronavirus Emerging in China—Key Questions for Impact Assessment. N. Engl. J. Med. 2020, 382, 692–694. [Google Scholar] [CrossRef] [PubMed]
- Johns Hopkins Coronavirus Resource Center. Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering. 2020. Available online: https://coronavirus.jhu.edu/map.html (accessed on 26 August 2020).
- Informe Sobre la Situación COVID-19 en España a 6 April 2020. Equipo COVID-19. RENAVE. CNE. CNM (ISCIII). Informe COVID-19 nº21. 6 April 2020. Available online: https://covid19.isciii.es/ (accessed on 6 April 2020).
- Imperial College COVID-19 Response Team. Report 13: Estimating the Number of Infections and the Impact of Non-Pharmaceutical Interventions on COVID-19 in 11 European Countries. March 2020. Available online: https://spiral.imperial.ac.uk:8443/handle/10044/1/77731 (accessed on 6 April 2020).
- Rothan, H.A.; Byrareddy, S.N. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J. Autoimmun. 2020, 109, 102433. [Google Scholar] [CrossRef] [PubMed]
- Liang, W.; Guan, W.; Chen, R.; Wang, W.; Li, J.; Xu, K.; Li, C.; Ai, Q.; Lu, W.; Liang, H.; et al. Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China. Lancet Oncol. 2020, 21, 335–337. [Google Scholar] [CrossRef]
- Sharpe, A.H.; Pauken, K.E. The diverse functions of the PD1 inhibitory pathway. Nat. Rev. Immunol. 2018, 18, 153–167. [Google Scholar] [CrossRef] [PubMed]
- Fisher, R.A. On the Interpretation of χ2 from Contingency Tables, and the Calculation of P. J. R. Stat. Soc. 1922, 85, 87. [Google Scholar] [CrossRef]
- Mehta, C.R.; Patel, N.R. A Network Algorithm for Performing Fisher’s Exact Test in r × c Contingency Tables. J. Am. Stat. Assoc. 1983, 78, 427–434. [Google Scholar] [CrossRef]
- Wilcoxon, F. Individual Comparisons by Ranking Methods. Biom. Bull. 1945, 1, 80. [Google Scholar] [CrossRef]
- R Core Team. R: A Language and Environment for Statistical Computing; R Foundation for Statistical Computing: Vienna, Austria, 2020; Available online: https://www.r-project.org/ (accessed on 16 September 2020).
- Kuderer, N.M.; Choueiri, T.K.; Shah, D.P.; Shyr, Y.; Rubinstein, S.M.; Rivera, D.R.; Shete, S.; Hsu, C.-Y.; Desai, A.; de Lima Lopes, G.; et al. Clinical impact of COVID-19 on patients with cancer (CCC19): A cohort study. Lancet 2020, 395, 1907–1918. [Google Scholar] [CrossRef]
- Zhang, L.; Zhu, F.; Xie, L.; Wang, C.; Wang, J.; Chen, R.; Jia, P.; Guan, H.; Peng, L.; Chen, Y.; et al. Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China. Ann. Oncol. 2020, 31, 894–901. [Google Scholar] [CrossRef] [PubMed]
- Winter, A.K.; Hegde, S.T. The important role of serology for COVID-19 control. Lancet Infect. Dis. 2020, 20, 758–759. [Google Scholar] [CrossRef]
- Venkatesulu, B.P.; Chandrasekar, V.T.; Girdhar, P.; Advani, P.; Sharma, A.; Elumalai, T.; Hsieh, C.; Elghazawy, H.I.; Verma, V.; Krishnan, S. A systematic review and meta-analysis of cancer patients affected by a novel coronavirus. medRxiv 2020. [Google Scholar] [CrossRef]
- Van Assen, S.; Holvast, A.; Benne, C.A.; Posthumus, M.D.; Van Leeuwen, M.A.; Voskuyl, A.E.; Blom, M.; Risselada, A.P.; De Haan, A.; Westra, J.; et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum. 2010, 62, 75–81. [Google Scholar] [CrossRef] [PubMed]
- Rousseau, B.; Loulergue, P.; Mir, O.; Krivine, A.; Kotti, S.; Viel, E.; Simon, T.; De Gramont, A.; Goldwasser, F.; Launay, O.; et al. Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: The VACANCE study. Ann. Oncol. 2012, 23, 450–457. [Google Scholar] [CrossRef] [PubMed]
- Di Cosimo, S.; Malfettone, A.; Pérez-García, J.M.; Llombart-Cussac, A.; Miceli, R.; Curigliano, G.; Cortes, J. Immune checkpoint inhibitors: A physiology-driven approach to the treatment of coronavirus disease 2019. Eur. J. Cancer 2020, 135, 62–65. [Google Scholar] [CrossRef] [PubMed]
- Bersanelli, M.; Scala, S.; Affanni, P.; Veronesi, L.; Colucci, M.E.; Banna, G.L.; Cortellini, A.; Liotta, F. Immunological insights on influenza infection and vaccination during immune checkpoint blockade in cancer patients. Immunotherapy 2020, 12, 105–110. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pollán, M.; Pérez-Gómez, B.; Pastor-Barriuso, R.; Oteo, J.; Hernán, M.A.; Pérez-Olmeda, M.; Sanmartín, J.L.; Fernández-García, A.; Cruz, I.; De Larrea, N.F.; et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): A nationwide, population-based seroepidemiological study. Lancet 2020, 396, 535–544. [Google Scholar] [CrossRef]
- Choe, P.G.; Perera, R.; Park, W.B.; Song, K.-H.; Bang, J.H.; Kim, E.S.; Bin Kim, H.; Ko, L.W.R.; Park, S.W.; Kim, N.-J.; et al. MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015. Emerg. Infect. Dis. 2017, 23, 1079–1084. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cao, W.-C.; Liu, W.; Zhang, P.-H.; Zhang, F.; Richardus, J. Disappearance of Antibodies to SARS-Associated Coronavirus after Recovery. N. Engl. J. Med. 2007, 357, 1162–1163. [Google Scholar] [CrossRef] [PubMed]
- Wu, L.-P.; Wang, N.-C.; Chang, Y.-H.; Tian, X.-Y.; Na, D.-Y.; Zhang, L.-Y.; Zheng, L.; Lan, T.; Wang, L.-F.; Liang, G. Duration of Antibody Responses after Severe Acute Respiratory Syndrome. Emerg. Infect. Dis. 2007, 13, 1562–1564. [Google Scholar] [CrossRef] [PubMed]
- Kissler, S.M.; Tedijanto, C.; Goldstein, E.; Grad, Y.H.; Lipsitch, M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science 2020, 368, 860–868. [Google Scholar] [CrossRef] [PubMed]
Characteristic | Overall Cohort with COVID-19 Number (%) (n = 43) |
---|---|
Age (median) | 73 (46–91) |
Male | 28 (65) |
Clinical Expression | |
Symptomatic | 37 (86) |
Asymptomatic | 6 (14) |
Cancer type | |
Breast | 4 (9.3) |
lung | 2 (4.7) |
Prostate | 9 (21) |
Kidney | 3 (7) |
Bladder | 4 (9.3) |
hematology | 11 (25.6) |
Colon | 4 (9.3) |
other | 6 (14) |
Outcomes | |
Hospitalization | 43 (100) |
Severe events | 14 (33) |
Intensive care unit | 6 (14) |
Death | 7 (16) |
Cancer Status | |
Remission or no evidence of disease | 29 (67) |
Present, stable | 11 (25.6) |
Present and metastasis | 3 (7.7) |
Anticancer Therapy | |
None a | 33 (76.7) |
Target therapy b | 4 (9.3) |
Hormonotherapy | 1 (2.3) |
Immunotherapy | 0 |
Chemotherapy c | 5 (12) |
Radiotherapy | 0 |
Seroprevalenced | n = 36 |
IgM−/IgG+ | 22 (61) |
IgM+/IgG+ | 8 (22) |
IgM−/IgG− | 6 (17) |
Characteristic | Overall Cohort Patients Number(%) (n = 166) |
---|---|
Age (median) | 63 (33–86) |
Male | 96 (57.8) |
Symptoms | |
Symptomatic | 112 (67.4) |
Asymptomatic | 7 (32.6) |
Cancer type | |
Breast | 31 (18.6) |
lung | 49 (29.5) |
Colon | 20 (12.5) |
Bladder | 9 (5.4) |
Gastric | 6 (3.61) |
Rectum | 6 (3.6) |
Ovary | 7 (4.2) |
ORL Hepatocarcinoma Pancreas Other | 6 (3.6) 4 (2.4) 5 (3.0) 23 (13.8) |
Stage | |
Stage IV | 137 (83.5) |
Stage III | 22 (13.2) |
Stage I-II | 5 (3.0) |
Anticancer Therapy | |
Chemotherapy | 78 (46.9) |
Immunotherapy | 58 (34.9) |
Targeted Therapy | 23 (13.8) |
Symptoms | |
Cough | 38 (22.8) |
Feber | 21 (12.6) |
Dyspnea | 28 (16.8) |
Odynophagia | 24 (14.4) |
Vomits | 13 (7.8) |
Diarrhea Asthenia Anosmia Headache Activity Reduction Medical Consultation Treatment Required Hospitalization | 34 (20.4) 77 (46.3) 27 (16.2) 28 (16.8) 35 (21.0) 26 (15.6) 24 (14.4) 10 (6.2) |
Seroprevalence | |
IgM−/IgG+ | 2 (1.2) |
IgM+/IgG+ | 1 (0.6) |
IgM−/IgG− | 163 (98.1) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Garde-Noguera, J.; Fernández-Murga, M.L.; Giner-Bosch, V.; Dominguez-Márquez, V.; Sánchez, J.G.; Soler-Cataluña, J.J.; López Chuliá, F.; Honrubia, B.; Piera, N.; Llombart-Cussac, A. Impact of SARS-CoV-2 Infection on Patients with Cancer: Retrospective and Transversal Studies in Spanish Population. Cancers 2020, 12, 3513. https://doi.org/10.3390/cancers12123513
Garde-Noguera J, Fernández-Murga ML, Giner-Bosch V, Dominguez-Márquez V, Sánchez JG, Soler-Cataluña JJ, López Chuliá F, Honrubia B, Piera N, Llombart-Cussac A. Impact of SARS-CoV-2 Infection on Patients with Cancer: Retrospective and Transversal Studies in Spanish Population. Cancers. 2020; 12(12):3513. https://doi.org/10.3390/cancers12123513
Chicago/Turabian StyleGarde-Noguera, Javier, M. Leonor Fernández-Murga, Vicent Giner-Bosch, Victoria Dominguez-Márquez, José García Sánchez, Juan José Soler-Cataluña, Franscica López Chuliá, Beatriz Honrubia, Nuria Piera, and Antonio Llombart-Cussac. 2020. "Impact of SARS-CoV-2 Infection on Patients with Cancer: Retrospective and Transversal Studies in Spanish Population" Cancers 12, no. 12: 3513. https://doi.org/10.3390/cancers12123513